The National Lipid Association (NLA) is an American non-profit multidisciplinary medical society that aims to enhance the practice of lipid management in clinical medicine. The NLA focuses on the prevention of cardiovascular disease and other lipid-related disorders.[1]
Overview
The National Lipid Association was formed in 1997 and has over 2,000 members.[2][3] It provides medical education for healthcare professionals and physicians to advance knowledge and certification in clinical lipidology.[2] Joseph Saseen is the current president of NLA.[4][5] In 2014, the NLA proposed a working definition of statin intolerance and made general recommendations for health professionals.[6][7]
The NLA have stated that by 2012, a wealth of evidence including numerous clinical trials examined by the Cholesterol Treatment Trialists' Collaboration has confirmed the lipid hypothesis.[8]
The NLA publishes the Journal of Clinical Lipidology.[9]
Scientific statements
In 2019, the NLA's Nutrition and Lifestyle Task Force published a scientific statement based on a comprehensive review of recent clinical evidence on the effects of low and very-low-carbohydrate diets on the management of body weight and other cardiometabolic risk factors.[10][11] The statement concluded that low and very-low-carbohydrate die are not superior to other dietary approaches for weight loss and are difficult to maintain in the long term.[10][11]
In 2021, the NLA published a scientific statement on lipid measurements in the management of cardiovascular diseases.[12]
In 2022, the NLA published a scientific statement on statin intolerance, updating the definition which now classifies statin intolerance as either partial or complete.[13] The 2022 statement recommends different strategies to help patients stay on statin medications, and alternative medications to those who cannot tolerate statins.[1][14]
Selected publications
- Cheeley MK, Saseen JJ, Agarwala A, Ravilla S, Ciffone N, Jacobson TA, Dixon DL, Maki KC (2022). "NLA scientific statement on statin intolerance: a new definition and key considerations for ASCVD risk reduction in the statin intolerant patient". J Clin Lipidol. 16 (4): 361–375. doi:10.1016/j.jacl.2022.05.068. PMID 35718660. S2CID 249868408.
{{cite journal}}: CS1 maint: multiple names: authors list (link)